-

Agilent to Webcast Second-Quarter Fiscal Year 2021 Financial Results Presentation

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release second-quarter fiscal year 2021 financial results after the stock market closes on Tuesday, May 25. The company will host a live webcast of its investor conference call in listen-only mode on the same day.

Details for the webcast:

Date: Tuesday, May 25, 2021
Time: 1:30 p.m. Pacific time
Web access: Links will be provided in the “News & Events -- Events” portion of the Investor Relations section of the Agilent website.

The webcast will remain on the company website for 90 days.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Contacts

Investor Contact:
Ruben DiRado
+1 408-345-8971
ruben_dirado@agilent.com

Media Contact:
Tom Beermann
+1 408-386-5892
tom.beermann@agilent.com

Industry:

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB
Release Summary
Agilent to announce fiscal second quarter financial results on May 25.
Release Versions
English
$Cashtags
$A
Hashtags
#Agilent
#Q2
#earnings

Contacts

Investor Contact:
Ruben DiRado
+1 408-345-8971
ruben_dirado@agilent.com

Media Contact:
Tom Beermann
+1 408-386-5892
tom.beermann@agilent.com

More News From Agilent Technologies Inc.

Agilent Reports First-Quarter Fiscal Year 2026 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.80 billion for the first quarter ended Jan. 31, 2026, representing growth of 7.0% reported and up 4.4% core(1) compared with the first quarter of 2025. First-quarter GAAP net income was $305 million, or $1.07 per share. This compares with $318 million, or $1.11 per share, in the first quarter of 2025. Non-GAAP(2) net income was $386 million, or $1.36 per share, during the quarter, compared wi...

Agilent to Participate in TD Cowen’s 46th Annual Health Care Conference

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Chief Financial Officer Adam Elinoff and Head of Investor Relations Tejas Savant will participate in a fireside chat at TD Cowen’s 46th Annual Health Care Conference. The event is scheduled for 11:10 to 11:40 a.m. EST on Tuesday, March 3, 2026, in Boston, Massachusetts. A live audio webcast and replay of the presentation will be available through Agilent’s Investor Relations website. About Agilent Tec...

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. PD-L1 IHC 22C3 pharm...
Back to Newsroom